Skip to main content

HSV Infection

2
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Medpace
MedpaceCINCINNATI, OH
1 program
1
PritelivirPhase 3Small Molecule
AiCuris
AiCurisGermany - Wuppertal
1 program
1
pritelivirPhase 3Small Molecule5 trials
Active Trials
NCT05844436Available
NCT05671029Completed64Est. May 2023
NCT05513625Completed16Est. Oct 2020
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AiCurispritelivir
AiCurispritelivir
AiCurispritelivir
AiCurispritelivir

Clinical Trials (5)

Total enrollment: 600 patients across 5 trials

NCT03073967AiCurispritelivir

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Start: May 2017Est. completion: Nov 2025158 patients
Phase 3Completed
NCT02871492AiCurispritelivir

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

Start: Nov 2016Est. completion: Oct 2017362 patients
Phase 2Completed
NCT05671029AiCurispritelivir

Thorough QT/QTc of Pritelivir in Healthy Subjects

Start: Dec 2022Est. completion: May 202364 patients
Phase 1Completed
NCT05513625AiCurispritelivir

Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

Start: Jul 2020Est. completion: Oct 202016 patients
Phase 1Completed
NCT05844436AiCurispritelivir

Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2

N/AAvailable

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.